Cambridge Cognition Holdings PLC Cognition Kit Feasibility Study (1943H)
August 16 2016 - 1:00AM
UK Regulatory
TIDMCOG
RNS Number : 1943H
Cambridge Cognition Holdings PLC
16 August 2016
16 August 2016
Cambridge Cognition Holdings Plc
('Cambridge Cognition' or the 'Company')
New Cognition Kit wearable enables real-time brain health
measurement
The neuroscience company Cambridge Cognition Holdings PLC
(Cambridge, UK - LSE: COG), which develops and markets near patient
technologies for the assessment of brain health to improve the drug
development process, has announced results from a new technology
feasibility study. The results demonstrate for the first time that
consumer grade wearables such as the Apple Watch(R) and Microsoft
Band can be used to accurately measure clinically relevant
cognitive performance in everyday life using the Company's new
Cognition Kit software.
Mental health conditions are among the leading causes of
disability worldwide. With more than 450 million people living with
mental illnesses, the cost of treatment and care to global
economies will double by 2030 to over $6 trillion (Source: World
Health Organization).
Current methods of brain health assessment rely on infrequent
snapshots to characterise impairment and recovery. Such sparse
sampling will often miss clinically significant changes, which can
impact on a patient's quality of life and limit the ability to
accurately measure the effect of intervention and treatment.
Cognition Kit is a wearable software platform developed under a
joint venture between Cambridge Cognition and London research
agency Ctrl Group to address this growing need. The technology will
enable doctors, scientists and patients to better understand and
manage day-to-day brain health by measuring the key biological and
psychological factors affecting mental performance accurately in
real time.
The new study shows for the first time that wearable consumer
devices can be used clinically to measure cognitive performance
accurately when programmed with the Cognition Kit software.
During the study participants wore a wearable device to monitor
their levels of stress and physiological activity using built-in
sensors of heart rate, galvanic skin response and skin
temperature.
Throughout each day, subjects completed game-like micro tests of
cognition on the device to measure attention, memory, mood and
reaction speed.
The 30 million data points recorded demonstrate distinct
patterns of performance within and across days, allowing a rich
picture of a subject's cognitive health to emerge. Cognition Kit
thus has the potential to revolutionise brain health treatment at
all stages - from patient assessments during the development of
disease-modifying interventions to monitoring of patient
health.
With drug development companies increasingly being required to
demonstrate clinical outcomes-based value of treatments in
patients, this Cognition Kit study provides evidence that new
technologies could transform healthcare and medical research in a
wearable health industry estimated to be worth $2 billion (Source:
Soreon Research Wearable Healthcare Report 2014).
Cambridge Cognition is in discussion with a number of
pharmaceutical partners following significant early interest
boosted by the results of the study and expects to sign the first
Cognition Kit contracts in the near future.
Francesca Cormack, PhD, Director of Research and Innovation,
Cambridge Cognition commented:
"This proof of concept study demonstrates for the first time
that these consumer devices are enabling the rapid and accurate
collection of largescale scientific datasets. This not only allows
dramatically more detailed knowledge of moment-by-moment brain
function but also opens up new possibilities to develop machine
learning algorithms that will enable earlier detection and
intervention in brain disorders."
Ben Fehnert, Co-founder of Ctrl Group and Director of Cognition
Kit commented:
"Simple, regular interaction with peoples own phones and
wearable devices is key to helping understand daily and longer term
fluctuations in cognitive function. This study is the first
demonstration of how Cognition Kit software can build a rich
picture of brain health using peoples own devices during their
daily lives."
Notes to editors
About Cognition Kit
Cognition Kit is a joint venture between Cambridge Cognition and
Ctrl Group formed in 2016 to develop digital health tools on mobile
and wearable devices. Cognition Kit software takes research out of
the lab and into daily life, enabling doctors, scientists and the
public to better understand and manage day-to-day brain health.
www.cognitionkit.com @cognitionkit press@cognitionkit.com
About Cambridge Cognition
Cambridge Cognition is a neuroscience digital health company
specialising in the precise measurement of clinical outcomes in
neurological disorders. The Company develops and markets validated
near patient assessment products using cognition as a biomarker to
improve understanding, diagnosis and treatment in brain health
worldwide.
Partners include the world's leading drug development companies,
academic institutions and public-private health organisations.
www.cambridgecognition.com @CANTABconnect press@camcog.com
About Ctrl Group
Ctrl Group believe that new technologies have the potential to
transform healthcare and medical research by increasing efficiency
and creating more personalised medicine. We are a team of
designers, researchers, software developers and healthcare experts
who work internationally with healthcare companies and providers
who want to use new technology to improve people's health.
www.ctrl-group.com @ctrl_group hello@ctrl-group.com
Enquiries
Cambridge Cognition Holdings PLC
Steven Powell, Chief Executive Tel: 01223 810
Officer 700
Noah Konig, Director of Product press@camcog.com
Marketing and Communications
finnCap Ltd (NOMAD and Joint Broker) Tel: 020 7220
0500
Geoff Nash / Simon Hicks (Corporate Finance)
Alice Lane (Corporate Broking)
Hybridan LLP (Joint Broker) Tel: 020 3764
2341
Claire Noyce (Corporate Broking)
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCPAMBTMBIBBTF
(END) Dow Jones Newswires
August 16, 2016 02:00 ET (06:00 GMT)